Search Results - (Author, Cooperation:A. Bitton)
-
1Latest Papers from Table of Contents or Articles in PressL. Jostins ; S. Ripke ; R. K. Weersma ; R. H. Duerr ; D. P. McGovern ; K. Y. Hui ; J. C. Lee ; L. P. Schumm ; Y. Sharma ; C. A. Anderson ; J. Essers ; M. Mitrovic ; K. Ning ; I. Cleynen ; E. Theatre ; S. L. Spain ; S. Raychaudhuri ; P. Goyette ; Z. Wei ; C. Abraham ; J. P. Achkar ; T. Ahmad ; L. Amininejad ; A. N. Ananthakrishnan ; V. Andersen ; J. M. Andrews ; L. Baidoo ; T. Balschun ; P. A. Bampton ; A. Bitton ; G. Boucher ; S. Brand ; C. Buning ; A. Cohain ; S. Cichon ; M. D'Amato ; D. De Jong ; K. L. Devaney ; M. Dubinsky ; C. Edwards ; D. Ellinghaus ; L. R. Ferguson ; D. Franchimont ; K. Fransen ; R. Gearry ; M. Georges ; C. Gieger ; J. Glas ; T. Haritunians ; A. Hart ; C. Hawkey ; M. Hedl ; X. Hu ; T. H. Karlsen ; L. Kupcinskas ; S. Kugathasan ; A. Latiano ; D. Laukens ; I. C. Lawrance ; C. W. Lees ; E. Louis ; G. Mahy ; J. Mansfield ; A. R. Morgan ; C. Mowat ; W. Newman ; O. Palmieri ; C. Y. Ponsioen ; U. Potocnik ; N. J. Prescott ; M. Regueiro ; J. I. Rotter ; R. K. Russell ; J. D. Sanderson ; M. Sans ; J. Satsangi ; S. Schreiber ; L. A. Simms ; J. Sventoraityte ; S. R. Targan ; K. D. Taylor ; M. Tremelling ; H. W. Verspaget ; M. De Vos ; C. Wijmenga ; D. C. Wilson ; J. Winkelmann ; R. J. Xavier ; S. Zeissig ; B. Zhang ; C. K. Zhang ; H. Zhao ; M. S. Silverberg ; V. Annese ; H. Hakonarson ; S. R. Brant ; G. Radford-Smith ; C. G. Mathew ; J. D. Rioux ; E. E. Schadt ; M. J. Daly ; A. Franke ; M. Parkes ; S. Vermeire ; J. C. Barrett ; J. H. Cho
Nature Publishing Group (NPG)
Published 2012Staff ViewPublication Date: 2012-11-07Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Colitis, Ulcerative/genetics/immunology/microbiology/physiopathology ; Crohn Disease/genetics/immunology/microbiology/physiopathology ; Genetic Predisposition to Disease/*genetics ; Genome, Human/genetics ; *Genome-Wide Association Study ; Haplotypes/genetics ; *Host-Pathogen Interactions/genetics/immunology ; Humans ; Inflammatory Bowel Diseases/*genetics/immunology/*microbiology/physiopathology ; Mycobacterium/*immunology/pathogenicity ; Mycobacterium Infections/genetics/microbiology ; Mycobacterium tuberculosis/immunology/pathogenicity ; Phenotype ; Polymorphism, Single Nucleotide/genetics ; Reproducibility of ResultsPublished by: -
2Articles: DFG German National LicensesWild, G. E. ; Waschke, K. A. ; Bitton, A. ; Thomson, A. B. R.
Oxford, UK : Blackwell Science Ltd
Published 2003Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : The clinical course of Crohn's disease after the induction of remission with medical therapy is characterized by unpredictable relapse.Aim : To evaluate three surrogate markers, intestinal permeability, mucosal TNFα and nuclear factor (NF)-κB/IκBα expression, in order to determine the relationship of these parameters to clinical relapse.Methods : Thirty patients with active Crohn's disease were treated with a 10 week course of prednisone using a tapering dosing regimen. Intestinal permeability (lactulose/mannitol [L/M ratio]) was determined at baseline and at the end of prednisone tapering. TNFα production and the levels of expression of NF-κB/IκBα were measured in colonic mucosal biopsies obtained after the induction of remission.Results : Twenty-two patients (73%) achieved remission and 50% of patients experienced a clinical relapse during the ensuing 12 months. Treatment with prednisone resulted in a significant decrease in the L/M ratio. Of the patients that relapsed, 75% had a raised L/M ratio at the time of remission compared with 20% of patients with a normal L/M ratio (P 〈 0.008; hazard ratio = 6.094; CI 1.55, 17.43). Mucosal TNFα production was greater in relapsers compared with those who remained in remission. The levels of NF-κB in relapsers were significantly greater and levels of cytosolic IκBα were significantly lower compared with those measured in patients who remained in remission.Conclusions : These findings underscore the importance of incorporating biological parameters of inflammation in determining the clinical course of Crohn's disease.Type of Medium: Electronic ResourceURL: -
3Articles: DFG German National LicensesAumais, G. ; Lefebvre, M. ; Tremblay, C. ; Bitton, A. ; Martin, F. ; Giard, A. ; Madi, M. ; Spénard, J.
Oxford, UK : Blackwell Science Ltd
Published 2003Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Objective : Patients with ulcerative proctitis may have rectal mucosal properties different from healthy volunteers. This project compared the pharmacokinetics of rectally administered mesalazine in these two populations.Methods : In two separate studies, nine patients with ulcerative proctitis and 16 healthy volunteers received a single 500 mg mesalazine suppository and then 500 mg every 8 h for 5 days. Blood samples were collected for 12 h in healthy volunteers and 30 h in patients, and urine for 24 h in healthy volunteers and 30 h in patients. Rectal biopsies were performed 8 h after the last dose.Results : After a single dose to patients, mean mesalazine half-life (s.d.) was 5.0 (3.6) h. At steady-state, means (s.d.) were 89.1 (78.9) ng/mL for Cmin, 361.1 (240.8) ng/mL for Cmax, and 7.1 (7.3) h for half-life. Mean (range) rectal mesalazine concentrations were 167 (1.4–541.6) ng/mg tissue. After a single dose in healthy volunteers, mean (s.d.) half-life was 4.0 (4.7) h. At steady-state, means (s.d.) were 22.4 (61.6) ng/mL for Cmin, 359.4 (166.3) ng/mL for Cmax, and 0.9 (0.5) h for half-life.Conclusion : Mesalazine is released in the rectum of patients, with a bioavailability of about 40%. Tissue distribution is also appreciable. Both parameters appear higher than in healthy volunteers.Type of Medium: Electronic ResourceURL: